2-methyl-6,7-dihydro-5H-pyrazole [5,1-b][1,3]oxazine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-6,7-dihydro-5H-pyrazole [5,1-b][1,3]oxazine
• 英文别名: 2-methyl-5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine；2-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine
• 化学式: C₇H₁₀N₂O
• 分子量: 138.169
• InChiKey: IAYQYIACQLHQAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-6,7-dihydro-5H-pyrazole [5,1-b][1,3]oxazine 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 potassium nitrate 作用下， 以 乙醇 为溶剂， 反应 17.5h， 生成 2-methyl-6,7-dihydro-5H-pyrazole [5,1-b][1,3]oxazin-3-amine
  参考文献：
  名称：

  黏着斑激酶抑制剂及其用途

  摘要：

  本发明属于药物领域，涉及一种黏着斑激酶抑制剂及其用途。具体的，本发明涉及一种新的黏着斑激酶抑制剂化合物，或其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或前药。本发明还涉及所述化合物和其药物组合物作为药物的用途，尤其是在制备用于治疗或预防癌症、肺动脉高压、病理性血管生成相关疾病的药物中的用途。

  公开号：

  CN108948019B
• 作为产物：
  描述：

  3-甲基-3-吡唑啉-5-酮 、 1,3-二溴丙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 以58.3%的产率得到2-methyl-6,7-dihydro-5H-pyrazole [5,1-b][1,3]oxazine
  参考文献：
  名称：

  黏着斑激酶抑制剂及其用途

  摘要：

  本发明属于药物领域，涉及一种黏着斑激酶抑制剂及其用途。具体的，本发明涉及一种新的黏着斑激酶抑制剂化合物，或其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或前药。本发明还涉及所述化合物和其药物组合物作为药物的用途，尤其是在制备用于治疗或预防癌症、肺动脉高压、病理性血管生成相关疾病的药物中的用途。

  公开号：

  CN108948019B

文献信息

• [EN] TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE FURANE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018097944A1

  公开（公告）日：2018-05-31

  Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.

  式(I)和式(II)的化合物，其药用盐，任何上述化合物的立体异构体，或它们的混合物是APJ受体的激动剂，并且在治疗心血管和其他疾病方面有用。式(I)和式(II)的化合物具有以下结构：(I); (II)。中间体(V)也被要求。
• [EN] BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION<br/>[FR] DÉRIVÉS DE BENZODIAZÉPINE UTILES POUR LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：REVIRAL LTD

  公开号：WO2022008911A1

  公开（公告）日：2022-01-13

  Benzodiazepine derivatives of formula (Ie) wherein one of R1 and R2 is a benzodiazepinyl-containing group of formula (II) in which R8 is H or halo; the other of R1 and R2 is a group Z selected from H, C3-C6 cycloalkyl, halo, -NHR9, benzyl, phenyl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, wherein phenyl, heterocyclyl and heteroaryl are unsubstituted or substituted by one or two substituents selected from 4- to 10-membered heterocyclyl which is unsubstituted or substituted by OR, and from C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, halo, -OR, -(CH2)mOR, -NR2, -(CH2)mNR2, -NHR", -SOmNR2, -SOmR, -SR, nitro, -CO2R, -CN, -CONR2, -NHCOR, -CH2NR10R11 and -NR10R11, in which each R is independently H or C1-C6 alkyl, R" is C3-C6 cycloalkyl and m is 1 or 2; R9 is selected from phenyl and 4- to 10-membered heteroaryl wherein phenyl and heteroaryl are unsubstituted or substituted by halo; R10 and R11 are each independently H or C1-C6 alkyl; or R10 and R11 form, together with the N atom to which they are attached, either (a) a morpholine ring which is optionally bridged by a -CH2- group linking two ring carbon atoms that are positioned para to each other, or (b) a spiro group of the following formula (b): and ring A is a ring of one of the following structural formulae (I-1), (I-2) and (I-3): and ring A is a ring of one of the following structural formulae (I-1), (1-2) and (1-3): in which Y is selected from O, S, SO2 and NR, wherein R is as defined above, and each of R2 to R7 is independently H, C1-C6 alkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, halo, -OR, -CH2OR, -NR2, -CH2NR12R13, -NRCOOR, -CH2OR, -SOmNR2, -SOmR, - CH2SOmR, nitro, -CO2R, -CN, -CONR2 or -NHCOR, in which R and m are as defined above and R12 and R13 are each independently H, C1-C6 alkyl, benzyl, 4- to 10-membered heterocyclyl or R12 and R13 form, together with the N atom to which they are attached, a 4- to 10-membered heteroaryl which is unsubstituted or a 4- to 10-membered heterocyclyl which is unsubstituted or substituted with C1-C6 alkyl or halo, or any two of R2 to R7 that bond to the same carbon atom form a spiro ring selected from a C3-C6 cycloalkyl spiro ring and a spiro oxetane ring of the following structure: (Formula A) and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

  苯二氮卓啉衍生物的化学式(Ie)，其中R1和R2中的一个是具有化学式(II)的苯二氮卓啉基团，其中R8为H或卤素；另一个是从H、C3-C6环烷基、卤素、-NHR9、苄基、苯基、4-到10元杂环烷基和4-到10元杂芳基中选择的基团Z，其中苯基、杂环烷基和杂芳基未被取代或被一个或两个取代基取代，所述取代基从未被取代或被OR取代的4-到10元杂环烷基和从C1-C6烷基、C1-C6羟基烷基、C1-C6卤基烷基、C3-C6环烷基、卤素、-OR、-(CH2)mOR、-NR2、-( )mNR2、-NHR"、-SOmNR2、-SOmR、-SR、硝基、-CO2R、-CN、-CONR2、-NHCOR、- NR10R11和-NR10R11中选择，其中每个R独立地为H或C1-C6烷基，R"为C3-C6环烷基，m为1或2；R9从苯基和4-到10元杂芳基中选择，其中苯基和杂芳基未被取代或被卤素取代；R10和R11各自独立地为H或C1-C6烷基；或R10和R11与它们连接的N原子一起形成(a)可以由连接两个对位的环碳原子的- -基团桥接的吗啡环，或(b)下列化学式(b)的螺环团，其中环A是以下结构式(I-1)、(I-2)和(I-3)之一的环，环A是以下结构式(I-1)、(1-2)和(1-3)之一的环，其中Y从O、S、SO2和NR中选择，其中R如上定义，R2到R7中的每一个独立地为H、C1-C6烷基、C1-C6羟基烷基、C3-C6环烷基、卤素、-OR、- OR、-NR2、- NR12R13、-NRCOOR、- OR、-SOmNR2、-SOmR、- SOmR、硝基、-CO2R、-CN、-CONR2或-NHCOR，其中R和m如上定义，R12和R13各自独立地为H、C1-C6烷基、苄基、4-到10元杂环烷基或R12和R13与它们连接的N原子一起形成未被取代的4-到10元杂芳基或未被取代或被C1-C6烷基或卤素取代的4-到10元杂环烷基，或结合到同一碳原子的R2到R7中的任意两个形成以下结构的螺环：(化学式A)，及其药学上可接受的盐是RSV的抑制剂，因此可以用来治疗或预防RSV感染。
• CHROMAN DERIVATIVES AS TRPM8 INHIBITORS
  申请人：AMGEN INC.

  公开号：US20140045855A1

  公开（公告）日：2014-02-13

  Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  Formula I的Chroman化合物和衍生物是TRPM8的有用抑制剂。这些化合物在治疗多种由TRPM8介导的疾病和症状方面具有用途，并可用于制备治疗这些疾病和症状的药物和药物组合物。这些疾病的例子包括，但不限于，偏头痛和神经病性疼痛。Formula I的化合物具有以下结构：变量的定义在此提供。
• TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
  申请人：Biswas Kaustav

  公开号：US20130157996A1

  公开（公告）日：2013-06-20

  Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  公式I的化合物可用作TRPM8的拮抗剂。这些化合物在治疗许多TRPM8介导的疾病和病症方面非常有用，并可用于制备用于治疗此类疾病和病症的药物和制剂。此类疾病的示例包括但不限于偏头痛和神经病性疼痛。公式I的化合物具有以下结构：其中变量的定义在此提供。
• ANDROGEN RECEPTOR MODULATING COMPOUNDS
  申请人：ORION CORPORATION

  公开号：US20150203479A1

  公开（公告）日：2015-07-23

  The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

  本公开涉及式(I)的化合物及其药学上可接受的盐。本公开还涉及包含式(I)的化合物及其药学上可接受的盐的组合物和治疗方法。